All In Biotech

Drug Trial Radar · NCT00143273

Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation

Dose Response Study Of Lasofoxifene In Postmenopausal Women With Osteoporosis (Placebo-Controlled, Multicenter, Double-Blind, Comparative Study) - Japanese Asian Dose Evaluation: JADE

Last checked: Nov 19, 2026Latest source record: Aug 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 497 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

497

Actual

Start

Jun 2004

Primary completion

Mar 2006

Study completion Mar 2006

Sponsor

Lead sponsor
Ligand PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 2, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To establish the optimal dose of lasofoxifene that is fully effective in increasing the BMD in postmenopausal Asian women.

Conditions

  • Osteoporosis

Interventions

  • lasofoxifeneDrug

    0.05 mg tablets

  • PlaceboDrug

    0 mg

  • LasofoxifeneDrug

    0.25 mg tablets

  • LasofoxifeneDrug

    0.5 mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effects of lasofoxifene compared to placebo on Bone Mineral Density (BMD) changes at the spine and hip after 1 year of treatmentTime frame: 12 months

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

  • Pfizer Investigational Site

    Fukuoka, Fukuoka, Japan

  • Pfizer Investigational Site

    Kagoshima, Kagoshima-ken, Japan

  • Pfizer Investigational Site

    Kagoshima, Kagoshima-ken, Japan

  • Pfizer Investigational Site

    Miyazaki, Miyazaki, Japan

  • Pfizer Investigational Site

    Fuchū, Tokyo, Japan

  • Pfizer Investigational Site

    Kiyose, Tokyo, Japan

  • Pfizer Investigational Site

    Minato-ku, Tokyo, Japan

  • Pfizer Investigational Site

    Minato-ku, Tokyo, Japan

  • Pfizer Investigational Site

    Setagaya-ku, Tokyo, Japan

  • Pfizer Investigational Site

    Yonago-shi, Tottori, Japan

  • Pfizer Investigational Site

    Kangnam-ku, Seoul, South Korea

  • Pfizer Investigational Site

    Sonpagu, Seoul, South Korea

  • Pfizer Investigational Site

    Youngdeungpo-gu, Seoul, South Korea

  • Pfizer Investigational Site

    Changhua, Taiwan

  • Pfizer Investigational Site

    Taipei, Taiwan

  • Pfizer Investigational Site

    Taoyun 333, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.